Valion Bio Welcomes Former U.S. Army Regulatory Leader and Biotech CEO Dr. Armand Balboni as Advisor in Run-up to Entolimod Therapeutic Efficacy Data Readout
Key Highlights
- ➤Valion Bio appoints Armand Balboni as advisor for Entolimod strategy and partnerships
- ➤Entolimod therapeutic efficacy study evaluates survival and gastrointestinal recovery after radiation exposure
- ➤Balboni cites Entolimod’s Fast Track and Orphan Drug designations
- ➤Entolimod studies are fully funded, according to Balboni
- ➤FDA Animal Rule provides Entolimod’s stated regulatory pathway
Expert Statements
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“Armand's experience spans several of the capabilities central to advancing Entolimod: drug development, regulatory execution, military medical requirements and procurement, and strategic partnerships.”
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“His mandate is to lead our scientific strategy and pursue government and industry partnerships to advance Entolimod toward its next development milestones.”
Armand Balboni, Advisor to Valion Bio
“After a career spent on both the government and industry sides of medical countermeasure development, I was selective about where to go next.”
Armand Balboni, Advisor to Valion Bio
“Valion stood out: a candidate with Fast Track and Orphan Drug designations, fully funded safety and therapeutic efficacy studies, and a clear regulatory pathway under the FDA's Animal Rule.”
Armand Balboni, Advisor to Valion Bio
“That combination is rare, and I am excited to help Dean and the team advance Entolimod.”
SAN ANTONIO, TX / ACCESS Newswire / November 19, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation, today announced that Armand Balboni, JD, MD, PhD, has become an Advisor on Valion's scientific strategy and medical countermeasure development efforts, with a focus on advancing Entolimod and pursuing government and strategic partnerships.
The advisory role brings together scientific, regulatory, and military medical expertise as Valion Bio prepares for a key development milestone for Entolimod, it's lead medical countermeasure candidate. Entolimod is currently advancing through a therapeutic efficacy study evaluating survival and gastrointestinal recovery following radiation exposure.
Get started
Create a free account to read the full story.
